We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Expert Opinion / Cases · March 01, 2021

BRAF Wildtype Melanoma Progressive on Nivolumab Monotherapy

Written by
Viola Franke MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Alexander van Akkooi

    I would start IPI/NIVO and consider SRT of the lesions. If asymptomatic, maybe first start 2nd line systemic therapy and a new brain MRI in 6 weeks time, but depending much on size and location.

  • Sep 21, 2021

    Pending Moderator approval.

Further Reading